Navigating Therapeutic Pathways and Transforming Care in ATTR-CM - Episode 5
Unmet Needs in ATTR-CM Care
The panel shifts to remaining unmet needs in ATTR-CM care, emphasizing that despite progress in diagnosis and available therapies, gaps persist across patient identification, treatment access, and long-term management. One ongoing challenge is recognizing early disease and distinguishing ATTR-CM from other common cardiac conditions, particularly in older adults with preserved ejection fraction. The experts stress that clinicians must think beyond labeling HFpEF as a final diagnosis by seeking its underlying cause. Therapeutically, the group notes that while stabilizers and silencers have expanded treatment options, navigating these therapies requires careful consideration of patient characteristics, tolerance, and evolving evidence. Cost and access barriers continue to affect who receives treatment and when. The panel also highlights the need for more data on disease monitoring and response assessment, particularly regarding biomarkers and imaging changes over time. Finally, greater patient and provider education, coordinated care pathways, and earlier referrals remain essential to improving outcomes.
The panel shifts to remaining unmet needs in ATTR-CM care, emphasizing that despite progress in diagnosis and available therapies, gaps persist across patient identification, treatment access, and long-term management. One ongoing challenge is recognizing early disease and distinguishing ATTR-CM from other common cardiac conditions, particularly in older adults with preserved ejection fraction. The experts stress that clinicians must think beyond labeling HFpEF as a final diagnosis by seeking its underlying cause.
Therapeutically, the group notes that while stabilizers and silencers have expanded treatment options, navigating these therapies requires careful consideration of patient characteristics, tolerance, and evolving evidence. Cost and access barriers continue to affect who receives treatment and when. The panel also highlights the need for more data on disease monitoring and response assessment, particularly regarding biomarkers and imaging changes over time. Finally, greater patient and provider education, coordinated care pathways, and earlier referrals remain essential to improving outcomes.
